The purpose of this research study is to determine the effectiveness and safety of envafolimab, an experimental drug that is not approved for use, when given alone or in combination with ipilimumab to stimulate the immune system to attack cancer cells. Both drugs are monoclonal antibodies, which are substances the body makes as part of an immune response (the body’s response to infection or something foreign to the body). Both drugs are designed to boost the immune response against cancer cells by overriding checkpoints that prevent immune cells from attacking cancer cells.
Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC)
OPEN TO ACCRUAL